Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 2:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 190 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo Niacin Clear all
Completed No phase listed Observational Accepts healthy volunteers

Observational Metabolic Health Study

NCT06790407
View directory record Official record
Conditions
Healthy
Interventions
Mimio Study Product, Placebo
Dietary Supplement
Lead sponsor
Mimio Health, Inc.
Industry
Eligibility
55 Years and older
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 10, 2025 · Synced Sep 10, 2026, 2:22 AM EDT
Completed Phase 2 Interventional Results available

Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab

NCT00939627
View directory record Official record
Conditions
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IVA Salivary Gland Cancer, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVA Verrucous Carcinoma of the Oral Cavity, Stage IVB Salivary Gland Cancer, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVB Verrucous Carcinoma of the Larynx, Stage IVB Verrucous Carcinoma of the Oral Cavity, Stage IVC Salivary Gland Cancer, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVC Verrucous Carcinoma of the Larynx, Stage IVC Verrucous Carcinoma of the Oral Cavity, Tongue Cancer, Untreated Metastatic Squamous Neck Cancer With Occult Primary
Interventions
cetuximab, placebo, sorafenib tosylate, laboratory biomarker analysis, quality-of-life assessment
Biological · Other · Drug + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
8
States / cities
Tampa, Florida • Atlanta, Georgia • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 10, 2026, 2:22 AM EDT
Completed Phase 2 Interventional Results available

The COMBINE Study: The CKD Optimal Management With BInders and NicotinamidE

NCT02258074
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Nicotinamide, Lanthanum Carbonate, Placebo (for Nicotinamide), Placebo (for lanthanum carbonate)
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
7
States / cities
San Diego, California • Denver, Colorado • Washington D.C., District of Columbia + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2021 · Synced Sep 10, 2026, 2:22 AM EDT
Completed Phase 2 Interventional Results available

1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy

NCT00493636
View directory record Official record
Conditions
Breast Cancer
Interventions
Gemcitabine, Sorafenib, Placebo, Capecitabine
Drug
Lead sponsor
Accelerated Community Oncology Research Network
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
44
States / cities
Anchorage, Alaska • Fayetteville, Arkansas • Corona, California + 37 more
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Sep 10, 2026, 2:22 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the EFFECTS of Acetylsalicylic Acid (ASA) on Niaspan®-Induced Flushing in Subjects With Dyslipidemia

NCT00626392
View directory record Official record
Conditions
Dyslipidemia
Interventions
niacin extended-release (NER), aspirin (ASA), aspirin placebo (ASA Pbo)
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
26
States / cities
Huntsville, Alabama • Scottsdale, Arizona • Tucson, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2009 · Synced Sep 10, 2026, 2:22 AM EDT
Completed Phase 2 Interventional Results available

Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer

NCT00813293
View directory record Official record
Conditions
Hepatocellular Cancer
Interventions
Sorafenib, radiofrequency ablation
Drug · Procedure
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Sep 10, 2026, 2:22 AM EDT
Not listed Phase 1 Interventional

Basis: Evaluating Sirtuin Supplements To Benefit Elderly Trauma Patients (BES2T BET)

NCT03635411
View directory record Official record
Conditions
Recovery of Function
Interventions
Nicotinamide Riboside and Pterostilbene, Placebo
Dietary Supplement
Lead sponsor
Elysium Health
Industry
Eligibility
65 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 5, 2020 · Synced Sep 10, 2026, 2:22 AM EDT
Completed Not applicable Interventional Results available

Diet, Exercise, Niacin, and Fenofibrate to Reduce Heart Disease Risk Factors in Individuals With HIV Lipodystrophy or Dyslipidemia

NCT00246376
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, HIV Infections, Hyperlipidemia, Hypertriglyceridemia, Insulin Resistance, Atherosclerosis
Interventions
Diet, Exercise, Niacin, Fenofibrate, Placebos
Behavioral · Drug · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 20, 2016 · Synced Sep 10, 2026, 2:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of NMN Supplementation on Organ System Biology

NCT04571008
View directory record Official record
Conditions
Glucose Metabolism Disorders
Interventions
Placebo, Treatment
Other · Dietary Supplement
Lead sponsor
Washington University School of Medicine
Other
Eligibility
45 Years to 75 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Sep 10, 2026, 2:22 AM EDT
Active, not recruiting Phase 2 Interventional

NIAGEN and Persistent Chemotherapy-Induced Peripheral Neuropathy

NCT04112641
View directory record Official record
Conditions
Chemotherapy-induced Peripheral Neuropathy
Interventions
Nicotinamide riboside, Placebo capsules
Drug
Lead sponsor
Donna Hammond, PhD
Other
Eligibility
18 Years to 85 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 10, 2026, 2:22 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older Adults

NCT07144527
View directory record Official record
Conditions
Aging, Frailty, Exercise Tolerance, Healthy Male and Female Subjects
Interventions
NMN, betaine, low-dose hydrogen peroxide (EGA), Nicotinamide Mononucleotide (NMN), Placebo
Dietary Supplement
Lead sponsor
Scott Silveira
Other
Eligibility
60 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Sep 10, 2026, 2:22 AM EDT
Completed Phase 3 Interventional

Trial of Vitamins in HIV Progression and Transmission

NCT00197743
View directory record Official record
Conditions
HIV Infections, Disease Transmission, Vertical
Interventions
Vitamin A + Beta Carotene, Multivitamins, Placebo
Dietary Supplement · Other
Lead sponsor
Harvard School of Public Health (HSPH)
Other
Eligibility
18 Years and older · Female only
Enrollment
1,085 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2003
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 10, 2010 · Synced Sep 10, 2026, 2:22 AM EDT
Completed Not applicable Interventional Results available

Study to Evaluate the Effect of Nicotinamide Riboside on Immunity

NCT02812238
View directory record Official record
Conditions
Atherosclerosis, Diabetes, Coronary Artery Disease
Interventions
Nicotinamide riboside (NR), Placebo
Dietary Supplement · Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 39 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 16, 2019 · Synced Sep 10, 2026, 2:22 AM EDT
Terminated Phase 3 Interventional Results available

Study of the Use of Niaspan for Treatment of Dyslipidemia in Diabetic Nephropathy

NCT00108485
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Kidney Failure, Chronic, Hyperlipidemia
Interventions
Extended release niacin, Placebo
Drug · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 21, 2016 · Synced Sep 10, 2026, 2:22 AM EDT
Completed Not applicable Interventional Results available

GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures

NCT03462680
View directory record Official record
Conditions
Parkinson's Disease
Interventions
niacin, placebo
Dietary Supplement · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
35 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Sep 10, 2026, 2:22 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Protection From Acute Kidney Injury (AKI) With Basis™ Treatment

NCT04342975
View directory record Official record
Conditions
AKI
Interventions
Nicotinamide Riboside + Pterostilbene, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Sep 10, 2026, 2:22 AM EDT
Recruiting Not applicable Interventional

Mechanistic Study of Nicotinamide Riboside on NAD+ Biology in Individuals With Combined Pulmonary Hypertension

NCT07563322
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Nicotinamide Riboside (NR), Placebo
Dietary Supplement · Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 10, 2026, 2:22 AM EDT
Completed Not applicable Interventional

Mitochondrial Cocktail for Gulf War Illness

NCT02804828
View directory record Official record
Conditions
Gulf War Syndrome, Persian Gulf Syndrome, Mitochondrial Disorders
Interventions
Individualized mitochondrial cocktail, Placebo
Dietary Supplement
Lead sponsor
University of California, San Diego
Other
Eligibility
48 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Sep 10, 2026, 2:22 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of the Relative Abuse Potential of Acurox Tablets in Non-Dependent Recreational Opioid Users

NCT01030406
View directory record Official record
Conditions
Opioid Abuse
Interventions
40/0mg taken first, 80/0mg taken first, 40/240mg taken first, 80/480mg taken first, 0/0mg taken first
Drug
Lead sponsor
Acura Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 31, 2018 · Synced Sep 10, 2026, 2:22 AM EDT
Completed Phase 3 Interventional Results available

Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis

NCT02066181
View directory record Official record
Conditions
Desmoid Fibromatosis
Interventions
Laboratory Biomarker Analysis, Placebo Administration, Quality-of-Life Assessment, Sorafenib Tosylate
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
149
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Arroyo Grande, California + 79 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Sep 10, 2026, 2:22 AM EDT
Completed Phase 4 Interventional Results available

Clinical Trial of Niagen to Examine Recovery in People With Persistent Cognitive and Physical Symptoms After COVID-19

NCT04809974
View directory record Official record
Conditions
Covid19, Sequelae of; Infection, Cognitive Symptom
Interventions
Niagen
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 4, 2025 · Synced Sep 10, 2026, 2:22 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Supplements for Controlling Resistance to Insulin

NCT00699413
View directory record Official record
Conditions
Obesity, Diabetes Mellitus, Type 2
Interventions
nutrition education plus active supplement, nutrition education plus inactive supplement
Drug
Lead sponsor
University of Southern California
Other
Eligibility
13 Years to 17 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2024 · Synced Sep 10, 2026, 2:22 AM EDT
Recruiting Phase 2 Interventional

Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia With History of Non-melanoma Skin Cancers

NCT04844528
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Non-melanoma Skin Cancer (NMSC)
Interventions
Nicotinamide, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Sep 10, 2026, 2:22 AM EDT
Completed Phase 3 Interventional Results available

A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma

NCT00105443
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Sorafenib (Nexavar, BAY43-9006), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
35
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2014 · Synced Sep 10, 2026, 2:22 AM EDT